Kathryn E. Reinicke, Ph.D.
Affiliations: | 2007 | Case Western Reserve University, Cleveland Heights, OH, United States |
Area:
Biochemistry, Cell BiologyGoogle:
"Kathryn Reinicke"Mean distance: (not calculated yet)
Parents
Sign in to add mentorDavid A. Boothman | grad student | 2007 | Case Western | |
(Prodrug development and the role of reactive oxygen species in beta-lapachone-mediated cell death.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Jayaraman S, Hou X, Kuffel MJ, et al. (2020) Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 51 |
Reid JM, Goetz MP, Buhrow SA, et al. (2014) Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies Cancer Chemotherapy and Pharmacology. 74: 1271-1278 |
Cao L, Li LS, Spruell C, et al. (2014) Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxidants & Redox Signaling. 21: 237-50 |
Bey EA, Reinicke KE, Srougi MC, et al. (2013) Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Molecular Cancer Therapeutics. 12: 2110-2120 |
Goetz M, Kuffel M, Reinicke K, et al. (2013) Abstract P5-09-08: A comparison of the non-genomic effects of endoxifen and tamoxifen in aromatase inhibitor resistant breast cancer: Differential effects on the estrogen receptor co-regulator SRC3 (AIB1) and identification of PKC and PI3K as endoxifen substrates Cancer Research. 73 |
Safgren SL, Buhrow SA, Walden C, et al. (2012) Abstract 3781: Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparativein vivoactivity studies Cancer Research. 72: 3781-3781 |
Reinicke KE, Hou X, Goetz MP, et al. (2011) Abstract 2283: Endoxifen exhibits potentin vitroandin vivoantitumor activity in ER+/HER2+ breast cancer and tamoxifen refractory tumors Cancer Research. 71: 2283-2283 |
Goetz M, Hou X, Suman V, et al. (2011) PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. Cancer Research. 71 |
Reinicke KE, Kuffel MJ, Goetz MP, et al. (2010) Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemotherapy and Pharmacology. 66: 575-83 |
Goetz M, Reinicke K, Reid J, et al. (2009) Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer. Cancer Research. 69: 2006-2006 |